This report contains market size and forecasts of Still's Disease Treatment in Global, including the following market information:
Global Still's Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Still's Disease Treatment market was valued at 1836.9 million in 2021 and is projected to reach US$ 2534.8 million by 2028, at a CAGR of 4.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Certolizumab Pegol Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Still's Disease Treatment include Biocon Limited, Epirus Biopharmaceuticals, Inc., Genor BioPharma Co., Ltd., Hetero Drugs Limited, Mabion SA, Mycenax Biotech Inc., Oncobiologics, Inc., Oncodesign SA and Panacea Biotec Limited, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Still's Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Still's Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Still's Disease Treatment Market Segment Percentages, by Type, 2021 (%)
Certolizumab Pegol
DNX-514
Etanercept
Others
Global Still's Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Still's Disease Treatment Market Segment Percentages, by Application, 2021 (%)
Clinic
Hospital
Others
Global Still's Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Still's Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Still's Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Still's Disease Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biocon Limited
Epirus Biopharmaceuticals, Inc.
Genor BioPharma Co., Ltd.
Hetero Drugs Limited
Mabion SA
Mycenax Biotech Inc.
Oncobiologics, Inc.
Oncodesign SA
Panacea Biotec Limited
Pfizer Inc.
Sandoz International GmbH
Swedish Orphan Biovitrum AB
Therapeutic Proteins International, LLC
UCB S.A.